← Leaderboards
Ying-Xian Pan
Sloan-Kettering Institute For Cancer Res
$18,635,688
Attributed
$19,369,652
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,369,652 · 12
By mechanism
R01$10,492,647 · 6
UG3$6,775,167 · 1
R21$1,495,038 · 3
R56$471,000 · 1
K01$135,800 · 1
Top collaborators
- Samie R Jaffrey2 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Gavril W Pasternak$18,579,552
- Yuri A Kolesnikov$219,655
- Grace C Rossi$117,208
Others in their field
Top investigators on “Opioid”
- Chanza Baytop · Westat, Inc.$271,217,917
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Sharon L. Walsh · University Of Kentucky$96,444,120
- Jeffrey H Samet · Boston University Medical Campus$95,014,310
- Edward V Nunes · Columbia University Health Sciences$85,118,880
Research focus
OpioidMorphineIn VivoMouse ModelRna SplicingVariantGenesMediatingAbsence Of Pain SensationProteinsKnockout MiceReceptorReceptor GeneExonsCellsRewardsOpioid AnalgesicsHeroinPharmacologyC-TerminalAnimal ModelMrna PrecursorAgonistPain Management
Grant awards (39)
Establishing Oprm1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management$773,957
R01 · FY2025 · DA · contact PI
Molecular mechanisms and functions underlying the role of Fto in mu opioid actions$717,345
R01 · FY2025 · DA · contact PI
Molecular mechanisms and functions underlying the role of Fto in mu opioid actions$750,583
R01 · FY2024 · DA · contact PI
Establishing Oprm1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management$709,572
R01 · FY2024 · DA · contact PI
Identifying novel molecular targets, signaling pathways and mechanisms underlying fentanyl overdose-induced severe respiratory depression and lethality in rats using TMT phosphoproteomics/proteomics$471,000
R56 · FY2023 · DA · contact PI
Pharmacology of opioid actions in vivo$361,100
R01 · FY2022 · DA · contact PI
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actions$365,003
R01 · FY2021 · DA · contact PI
Pharmacology of opioid actions in vivo$360,909
R01 · FY2021 · DA · contact PI
Arylepoxamides: A new class of potent, safer analgesics$329,534
UG3 · FY2021 · DA · contact PI
Arylepoxamides: A new class of potent, safer analgesics$3,182,170
UG3 · FY2020 · DA · contact PI
Pharmacology of opioid actions in vivo$330,459
R01 · FY2020 · DA · contact PI
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actions$307,853
R01 · FY2020 · DA · contact PI
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actions$82,891
R01 · FY2020 · DA · contact PI
Pharmacology of opioid actions in vivo$32,628
R01 · FY2020 · DA · contact PI
Arylepoxamides: A new class of potent, safer analgesics$3,263,463
UG3 · FY2019 · DA · contact PI
Pharmacology of opioid actions in vivo$413,080
R01 · FY2019 · DA · contact PI
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actions$390,744
R01 · FY2019 · DA · contact PI
Mapping mu agonist-induced receptor-protein interactions for OPRM1 7TM variants$229,630
R21 · FY2019 · DA · contact PI
Synthesis and pharmacology of novel opiates and their modulatory systems$464,335
R01 · FY2018 · DA · contact PI
Pharmacology of opioid actions in vivo$394,910
R01 · FY2018 · DA · contact PI
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actions$375,246
R01 · FY2018 · DA · contact PI
Mapping mu agonist-induced receptor-protein interactions for OPRM1 7TM variants$271,946
R21 · FY2018 · DA · contact PI
Alternative pre-mRNA splicing of mu opioid receptor gene and mu opioid actions$391,311
R01 · FY2017 · DA · contact PI
Exploring function of mu opioid receptor splice variants in rat by gene targeting$214,250
R21 · FY2017 · DA · contact PI
Exploring function of mu opioid receptor splice variants in rat by gene targeting$257,100
R21 · FY2016 · DA · contact PI
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRM$359,152
R01 · FY2012 · DA · contact PI
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRM$359,152
R01 · FY2011 · DA · contact PI
Exploring functions of mu opioid receptor carboxyl termini by gene targeting$283,487
R21 · FY2011 · DA · contact PI
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRM$370,260
R01 · FY2010 · DA · contact PI
Exploring functions of mu opioid receptor carboxyl termini by gene targeting$238,625
R21 · FY2010 · DA · contact PI
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRM$9,855
R01 · FY2010 · DA · contact PI
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRM$374,000
R01 · FY2009 · DA · contact PI
Characterizing exon 11 promoter of the mu opioid receptor gene, OPRM$374,000
R01 · FY2008 · DA · contact PI
Characterizing a novel promoter of mouse MOR-1 gene$316,143
R01 · FY2006 · DA · contact PI
Characterizing a novel promoter of mouse MOR-1 gene$277,375
R01 · FY2005 · DA
Characterizing a novel promoter of mouse MOR-1 gene$277,375
R01 · FY2004 · DA
Characterizing a novel promoter of mouse MOR-1 gene$277,375
R01 · FY2003 · DA
Characterizing a novel promoter of mouse MOR-1 gene$276,034
R01 · FY2002 · DA
CHARACTERIZING OPIOID RECEPTOR FUNCTIONS--GENE TARGETING$135,800
K01 · FY2000 · DA